Mycobacterial infections in organ transplant recipients

George T. John, Shankar Viswanathan

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Tuberculosis has a major adverse impact on solid organ transplant recipients; this article attempts to define this fact. The prevalence of posttransplant tuberculosis is increasing globally and currently is 13.7% at our center. The transplant surgery divides the continuum of pretransplant tuberculosis and posttransplant tuberculosis; immunosuppression accounts for a greater severity of the latter. Cyclosporin and tacrolimus are associated with an earlier onset of tuberculosis when compared with prednisolone and azathioprine immunosuppression. Disseminated disease is more common in nonrenal transplants. The risk for developing posttransplant tuberculosis in renal transplant recipients increased 2.25 times independently with cytomegalovirus (CMV) and twice with chronic liver disease; OKT3 treatment enhances the risk 1.8-fold. Tuberculosis occurring after 2 years of transplantation, diabetes mellitus, posttransplant diabetes mellitus, chronic liver disease, CMV, and deep mycoses each independently confer a risk, 1.5-times or higher, for death. Disseminated disease entails a 2-fold risk. Treatment with or without rifampicin is possible; the former is associated with a higher risk for allograft rejection. Isoniazid prophylaxis is recommended for high-risk patients with apparent clinical efficacy. However, in endemic areas, attendant liver disease makes it a difficult goal.

Original languageEnglish (US)
Pages (from-to)274-283
Number of pages10
JournalSeminars in Respiratory Infections
Volume17
Issue number4
DOIs
StatePublished - Dec 2002
Externally publishedYes

Fingerprint

Tuberculosis
Transplants
Infection
Liver Diseases
Cytomegalovirus
Immunosuppression
Diabetes Mellitus
Chronic Disease
Renal Tuberculosis
Muromonab-CD3
Mycoses
Isoniazid
Azathioprine
Tacrolimus
Rifampin
Prednisolone
Cyclosporine
Allografts
Transplant Recipients
Transplantation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Microbiology (medical)

Cite this

Mycobacterial infections in organ transplant recipients. / John, George T.; Viswanathan, Shankar.

In: Seminars in Respiratory Infections, Vol. 17, No. 4, 12.2002, p. 274-283.

Research output: Contribution to journalArticle

@article{b89ddf8aaba948e689e442e53188bbe0,
title = "Mycobacterial infections in organ transplant recipients",
abstract = "Tuberculosis has a major adverse impact on solid organ transplant recipients; this article attempts to define this fact. The prevalence of posttransplant tuberculosis is increasing globally and currently is 13.7{\%} at our center. The transplant surgery divides the continuum of pretransplant tuberculosis and posttransplant tuberculosis; immunosuppression accounts for a greater severity of the latter. Cyclosporin and tacrolimus are associated with an earlier onset of tuberculosis when compared with prednisolone and azathioprine immunosuppression. Disseminated disease is more common in nonrenal transplants. The risk for developing posttransplant tuberculosis in renal transplant recipients increased 2.25 times independently with cytomegalovirus (CMV) and twice with chronic liver disease; OKT3 treatment enhances the risk 1.8-fold. Tuberculosis occurring after 2 years of transplantation, diabetes mellitus, posttransplant diabetes mellitus, chronic liver disease, CMV, and deep mycoses each independently confer a risk, 1.5-times or higher, for death. Disseminated disease entails a 2-fold risk. Treatment with or without rifampicin is possible; the former is associated with a higher risk for allograft rejection. Isoniazid prophylaxis is recommended for high-risk patients with apparent clinical efficacy. However, in endemic areas, attendant liver disease makes it a difficult goal.",
author = "John, {George T.} and Shankar Viswanathan",
year = "2002",
month = "12",
doi = "10.1053/srin.2002.36445",
language = "English (US)",
volume = "17",
pages = "274--283",
journal = "Seminars in Respiratory Infections",
issn = "0882-0546",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Mycobacterial infections in organ transplant recipients

AU - John, George T.

AU - Viswanathan, Shankar

PY - 2002/12

Y1 - 2002/12

N2 - Tuberculosis has a major adverse impact on solid organ transplant recipients; this article attempts to define this fact. The prevalence of posttransplant tuberculosis is increasing globally and currently is 13.7% at our center. The transplant surgery divides the continuum of pretransplant tuberculosis and posttransplant tuberculosis; immunosuppression accounts for a greater severity of the latter. Cyclosporin and tacrolimus are associated with an earlier onset of tuberculosis when compared with prednisolone and azathioprine immunosuppression. Disseminated disease is more common in nonrenal transplants. The risk for developing posttransplant tuberculosis in renal transplant recipients increased 2.25 times independently with cytomegalovirus (CMV) and twice with chronic liver disease; OKT3 treatment enhances the risk 1.8-fold. Tuberculosis occurring after 2 years of transplantation, diabetes mellitus, posttransplant diabetes mellitus, chronic liver disease, CMV, and deep mycoses each independently confer a risk, 1.5-times or higher, for death. Disseminated disease entails a 2-fold risk. Treatment with or without rifampicin is possible; the former is associated with a higher risk for allograft rejection. Isoniazid prophylaxis is recommended for high-risk patients with apparent clinical efficacy. However, in endemic areas, attendant liver disease makes it a difficult goal.

AB - Tuberculosis has a major adverse impact on solid organ transplant recipients; this article attempts to define this fact. The prevalence of posttransplant tuberculosis is increasing globally and currently is 13.7% at our center. The transplant surgery divides the continuum of pretransplant tuberculosis and posttransplant tuberculosis; immunosuppression accounts for a greater severity of the latter. Cyclosporin and tacrolimus are associated with an earlier onset of tuberculosis when compared with prednisolone and azathioprine immunosuppression. Disseminated disease is more common in nonrenal transplants. The risk for developing posttransplant tuberculosis in renal transplant recipients increased 2.25 times independently with cytomegalovirus (CMV) and twice with chronic liver disease; OKT3 treatment enhances the risk 1.8-fold. Tuberculosis occurring after 2 years of transplantation, diabetes mellitus, posttransplant diabetes mellitus, chronic liver disease, CMV, and deep mycoses each independently confer a risk, 1.5-times or higher, for death. Disseminated disease entails a 2-fold risk. Treatment with or without rifampicin is possible; the former is associated with a higher risk for allograft rejection. Isoniazid prophylaxis is recommended for high-risk patients with apparent clinical efficacy. However, in endemic areas, attendant liver disease makes it a difficult goal.

UR - http://www.scopus.com/inward/record.url?scp=0036900887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036900887&partnerID=8YFLogxK

U2 - 10.1053/srin.2002.36445

DO - 10.1053/srin.2002.36445

M3 - Article

C2 - 12497544

AN - SCOPUS:0036900887

VL - 17

SP - 274

EP - 283

JO - Seminars in Respiratory Infections

JF - Seminars in Respiratory Infections

SN - 0882-0546

IS - 4

ER -